A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer
AbstractHepatocellular carcinoma (HCC) is the third most deadly cancer in the world. New treatment strategies are desperately needed due to limited standard therapies. Activation of the Erk, Akt, and STAT3pathways is implicated in the prognosis of HCC. The Se,Se′-1,4-phenylenebis(1,2-ethanediyl) bisisoselenourea (PBISe), is a selenium-containing MAPK and PI3 kinase inhibitor, effectively inhibit tumorigenesis in a variety of experimental models. The aim of our study is to demonstrate the potential role of PBISe in the treatment of HCC. The anti-proliferative and pro-apoptotic ability of PBISe is studied in vitro in four human HCC cell lines and in vivo in a spontaneous murine HCC model. Inhibition of cancer growth was performed by cell viability assay and apoptosis by caspase 3/7, PARP cleavage, annexin-V, and TUNEL assays. Role of PBISe on PI3 kinase, MAPK and STAT3 signaling is determined by Western blotting. In vivo effects of PBISe on tumor sizes were monitored using MRI in a spontaneous murine HCC. Liver tissues from the PBISe-treated mice are analyzed for angiogenesis, proliferation, and signaling pathway markers. Overall, PBISe activated caspase-3/7 and increased DNA fragmentation, which is positively correlated with the increased PARP cleavage. PBISe promoted apoptosis by inhibiting PI3K, MAPK, and STAT3 signaling with significant reduction in the tumor sizes (p < 0.007). PBISe-treated tumors reduced survival marker PCNA, and angiogenesis markers Vegf-A, Vegf-R3 and CD34. These results demonstrate the chemotherapeutic effects of PBISe, by inhibiting tumor growth and facilitating tumor apoptosis for HCC treatment. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Tagaram, H.R.S.; Desai, D.; Li, G.; Liu, D.; Rountree, C.B.; Gowda, K.; Berg, A.; Amin, S.; Staveley-O’Carroll, K.F.; Kimchi, E.T. A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer. Pharmaceuticals 2016, 9, 18.
Tagaram HRS, Desai D, Li G, Liu D, Rountree CB, Gowda K, Berg A, Amin S, Staveley-O’Carroll KF, Kimchi ET. A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer. Pharmaceuticals. 2016; 9(2):18.Chicago/Turabian Style
Tagaram, Hephzibah R.S.; Desai, Dhimant; Li, Guangfu; Liu, Dai; Rountree, C. B.; Gowda, Kavitha; Berg, Arthur; Amin, Shantu; Staveley-O’Carroll, Kevin F.; Kimchi, Eric T. 2016. "A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer." Pharmaceuticals 9, no. 2: 18.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.